MEDICAL DELIVERY DEVICE FOR THERAPEUTIC PROTEINS BASED ON SINGLE DOMAIN ANTIBODIES

• US 20100226920A1
• Filed: 03/26/2007
• Published: 09/09/2010
• Est. Priority Date: 03/27/2006
• Status: Abandoned Application

• Current Assignee: Ablynx NV (Sanofi )
• Original Assignee: Ablynx NV (Sanofi )
• Inventors: Landolt, Gerrit Franciscus, Dreier, Torsten
• Application Number:
  US12/225,644
• Publication Number:
  US 20100226920A1
• Time in Patent Office: Days
• US Class Current: 424/134.100
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61K 2039/54 characterised by the route of administration
• CPC Class Codes: A61M 5/28 Syringe ampoules or carpules, i.e. ampoules or carpules provided with a needle
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: C07K 16/00 Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies antibodies with enzymatic activity, e.g. abzymes C12N9/0002
• CPC Class Codes: C07K 2317/22 from camelids, e.g. camel, llama or dromedary
• CPC Class Codes: C07K 2317/569 Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®

Abstract

The present invention relates to a pen-style administration device for administering therapeutic or diagnostic therapeutic proteins that are based on single domain antibodies, and methods of using such a device in therapies or diagnoses.

Claims

1. A pen-style administration device comprising a housing, a reservoir constructed and arranged to hold a liquid medicine or diagnostic, the reservoir disposed in said housing and in fluid connection with an outlet, the outlet constructed and arranged for administering a liquid medicine or a diagnostic to a subject, wherein the liquid medicine or the diagnostic comprises a single domain antibody or a polypeptide construct containing at least one single domain antibody.

2. The administration device of claim 1, wherein the outlet comprises an injection needle.

3. The administration device of claim 1, wherein the administration device comprises an actuator for dispensing the liquid medicine or diagnostic from the reservoir.

4. The administration device of claim 1, wherein the administration device is adjustable for delivering variable doses of liquid medicine or diagnostic.

5. The administration device of claim 1, wherein the administration device is a pre-filled syringe for single use or multiple uses.

6. The administration device of claim 1, wherein the polypeptide construct comprises at least two single domain antibodies.

7. The administration device of claim 6, wherein the single domain antibodies are connected by a chemical linker or a peptide linker.

8. The administration device of claim 6, wherein the single domain antibodies bind to at least two different targets.

9. The administration device of claim 8, wherein at least one of the targets is a serum protein.

10. The administration device of claim 9, wherein the serum protein is serum albumin, serum immunoglobulin, thyroxine-binding protein, transferrin or fibrinogen.

11. The administration device of claim 9, wherein the binding of the single domain antibodies to the serum protein increases the half-life of the polypeptide construct.

12. The administration device of claim 1, wherein the polypeptide construct comprises a non-single domain antibody functional group or is connected to a non-single domain antibody functional group by a linker.

13. The administration device of claim 12, wherein the linker is a chemical linker or a peptide linker.

14. The administration device of claim 12, wherein the non-single domain antibody functional group is a serum protein.

15. The administration device of claim 14, wherein the serum protein is serum albumin, serum immunoglobulin, thyroxine-binding protein, transferrin or fibrinogen.

16. The administration device of claim 14, wherein the serum protein increases the half-life of the polypeptide construct.

17. The administration device of claim 1, wherein the single domain antibody is a V_H or V_HH.

18. The administration device of claim 1, wherein the single domain antibody is a camelized V_H.

19. The administration device of claim 1, wherein the single domain antibody is a humanized V_HH.

20. A method for treating and/or preventing and/or alleviating a disorder or disease state comprising administering to a subject in need of such a treatment an effective amount of a liquid medicine using the administration device of claim 1.

21. A method for diagnosing a disorder or a disease state comprising administering to a subject an effective amount of a diagnostic by using the administration device of claim 1.

22. The method of claim 20, wherein the disorder is an inflammatory disorder, an autoimmune disease, a cancer, a neurodegenerative disorder or a genetic disorder.

23. The method of claim 20, wherein the single domain antibody binds to a target of foreign origin.

24. The method of claim 23, wherein the target of foreign origin is a virus, a bacteria, a toxin, a radioactive compound or a drug.

25. The method of claim 20, wherein the single domain antibody binds to a host derived cellular target.

26. The method of claim 20, wherein the single domain antibody binds to a host derived non-cellular target.

27. The method of claim 21, wherein the disorder is an inflammatory disorder, an autoimmune disease, a cancer, a neurodegenerative disorder or a genetic disorder.

28. The method of claim 21, wherein the single domain antibody binds to a target of foreign origin.

29. The method of claim 28, wherein the target of foreign origin is a virus, a bacteria, a toxin, a radioactive compound or a drug.

30. The method of claim 21, wherein the single domain antibody binds to a host derived cellular target.

31. The method of claim 21, wherein the single domain antibody binds to a host derived non-cellular target.